-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, a multi-center real-world study (KCSG LU20-11) from Korea was published in the journal Cancer , which mainly evaluated patients with advanced or metastatic non-small cell lung cancer (NSCLC) who completed 2 years of immunotherapy (ICI) or immunotherapy.
Long-term survival prognostic outcomes in patients who discontinued treatment but did not progress after 6 months .
Long-term survival prognostic outcomes in patients who discontinued treatment but did not progress after 6 months .
To assess long-term survival outcomes in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have completed 2 years of immunotherapy (ICI) or been discontinued after 6 months of immunotherapy without progression .
We retrospectively studied 139 patients with advanced NSCLC (including 96 patients who completed 2 years of ICI therapy and 43 patients who discontinued ICI therapy after more than 6 months of treatment without disease progression) from 11 centers in Korea
.
ICI treatment started from August 2017 to December 2020
.
We retrospectively studied 139 patients with advanced NSCLC (including 96 patients who completed 2 years of ICI therapy and 43 patients who discontinued ICI therapy after more than 6 months of treatment without disease progression) from 11 centers in Korea
Of the 96 patients who completed 2 years of ICI therapy, 85.
Median OS was not reached, and the estimated OS rate at 12 months after discontinuation of ICIs was 96.
4%
Median OS was not reached, and the estimated OS rate at 12 months after discontinuation of ICIs was 96.
Among the 43 patients who discontinued ICI treatment after more than 6 months without disease progression, the median treatment time was 10.
5 months, and the median follow-up time was 21.
Among the 43 patients who discontinued ICI treatment after more than 6 months without disease progression, the median treatment time was 10.
Median OS was not reached, and the 12-month OS rate was 90.
However, after interruption of ICIs, median PFS was not reached in patients who achieved CR and PR and SD (P = .
145); furthermore, median OS was not achieved in patients who achieved CR and PR and SD (P = .
However, after interruption of ICIs, median PFS was not reached in patients who achieved CR and PR and SD (P = .
In conclusion, the study showed that patients with advanced or metastatic non-small cell lung cancer (NSCLC) who completed 2 years of immunotherapy (ICI) or discontinued immunotherapy after 6 months without progression had a long-term survival prognosis
.
In conclusion, the study showed that patients with advanced or metastatic non-small cell lung cancer (NSCLC) who completed 2 years of immunotherapy (ICI) or discontinued immunotherapy after 6 months without progression had a long-term survival prognosis
.
Studies have shown that patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have completed 2 years of immunotherapy (ICI) or been discontinued after 6 months of immunotherapy without progression have long-term survival outcomes
.
Studies have shown that patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have completed 2 years of immunotherapy (ICI) or been discontinued after 6 months of immunotherapy without progression have long-term survival outcomes
.
Original source:
Original source:Kim H, Kim DW, Kim M, Lee Y, Ahn HK, Cho JH, Kim IH, Lee YG, Shin SH, Park SE, Jung J, Kang EJ, Ahn MJ.
Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
Cancer.
2022 Feb 15;128(4): 778-787.
doi: 10.
1002/cncr.
33984.
Epub 2021 Oct 27.
PMID: 34705268.
Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
Cancer.
2022 Feb 15;128(4): 778-787.
doi: 10.
1002/cncr.
33984.
Epub 2021 Oct 27.
PMID: 34705268.
Leave a comment here
